V Marco Ranieri1, Ville Pettilä2, Matti K Karvonen3, Juho Jalkanen3, Peter Nightingale4, David Brealey5, Jordi Mancebo6, Ricard Ferrer7, Alain Mercat8, Nicolò Patroniti9, Michael Quintel10, Jean-Louis Vincent11, Marjatta Okkonen2, Ferhat Meziani12, Giacomo Bellani13, Niall MacCallum5, Jacques Creteur11, Stefan Kluge14, Antonio Artigas-Raventos15, Mikael Maksimow3, Ilse Piippo3, Kati Elima16, Sirpa Jalkanen16, Markku Jalkanen3, Geoff Bellingan5. 1. Alma Mater Studiorum-Università di Bologna, Dipartimento di Scienze Mediche e Chirurgiche, Anesthesia and Intensive Care Medicine, Policlinico di Sant'Orsola, Bologna, Italy. 2. Division of Intensive Care, Department of Anesthesiology, Intensive Care, and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 3. Faron Pharmaceuticals Ltd, Turku, Finland. 4. Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom. 5. Critical Care, University College London Hospitals, NHS Foundation Trust and National Institute for Health Research Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London, London, United Kingdom. 6. Department of Intensive Care, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain. 7. Department of Intensive Care/SODIR Research Group-VHIR Hospital Universitari Vall d'Hebron UCI, Barcelona, Spain. 8. Médecine Intensive-Réanimation CHU d'Angers, Université d'Angers, Angers, France. 9. Dipartimento di scienze diagnostiche e integrate, Università degli studi di Genova, Genova, Italy. 10. Anesthesiology and Operative Intensive Care Medicine, Universitätsmedizin Göttingen, Göttingen, Germany. 11. Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. 12. Université de Strasbourg (UNISTRA), Faculté de Médecine, Hôpitaux universitaires de Strasbourg, Nouvel Hôpital Civil, Service de réanimation, Strasbourg, France. 13. Azienda Ospedaliera San Gerardo, Milan, Italy. 14. Department of Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 15. Corporacion Sanitaria Universitaria Parc Tauli CIBER Enfermedades Respiratorias Autonomous University of Barcelona, Sabadell, Spain. 16. Medicity research Laboratory, University of Turku, Turku, Finland.
Abstract
Importance: Acute respiratory distress syndrome (ARDS) is associated with high mortality. Interferon (IFN) β-1a may prevent the underlying event of vascular leakage. Objective: To determine the efficacy and adverse events of IFN-β-1a in patients with moderate to severe ARDS. Design, Setting, and Participants: Multicenter, randomized, double-blind, parallel-group trial conducted at 74 intensive care units in 8 European countries (December 2015-December 2017) that included 301 adults with moderate to severe ARDS according to the Berlin definition. The radiological and partial pressure of oxygen, arterial (Pao2)/fraction of inspired oxygen (Fio2) criteria for ARDS had to be met within a 24-hour period, and the administration of the first dose of the study drug had to occur within 48 hours of the diagnosis of ARDS. The last patient visit was on March 6, 2018. Interventions: Patients were randomized to receive an intravenous injection of 10 μg of IFN-β-1a (144 patients) or placebo (152 patients) once daily for 6 days. Main Outcomes and Measures: The primary outcome was a score combining death and number of ventilator-free days at day 28 (score ranged from -1 for death to 27 if the patient was off ventilator on the first day). There were 16 secondary outcomes, including 28-day mortality, which were tested hierarchically to control type I error. Results: Among 301 patients who were randomized (mean age, 58 years; 103 women [34.2%]), 296 (98.3%) completed the trial and were included in the primary analysis. At 28 days, the median composite score of death and number of ventilator-free days at day 28 was 10 days (interquartile range, -1 to 20) in the IFN-β-1a group and 8.5 days (interquartile range, 0 to 20) in the placebo group (P = .82). There was no significant difference in 28-day mortality between the IFN-β-1a vs placebo groups (26.4% vs 23.0%; difference, 3.4% [95% CI, -8.1% to 14.8%]; P = .53). Seventy-four patients (25.0%) experienced adverse events considered to be related to treatment during the study (41 patients [28.5%] in the IFN-β-1a group and 33 [21.7%] in the placebo group). Conclusions and Relevance: Among adults with moderate or severe ARDS, intravenous IFN-β-1a administered for 6 days, compared with placebo, resulted in no significant difference in a composite score that included death and number of ventilator-free days over 28 days. These results do not support the use of IFN-β-1a in the management of ARDS. Trial Registration: ClinicalTrials.gov Identifier: NCT02622724.
RCT Entities:
Importance: Acute respiratory distress syndrome (ARDS) is associated with high mortality. Interferon (IFN) β-1a may prevent the underlying event of vascular leakage. Objective: To determine the efficacy and adverse events of IFN-β-1a in patients with moderate to severe ARDS. Design, Setting, and Participants: Multicenter, randomized, double-blind, parallel-group trial conducted at 74 intensive care units in 8 European countries (December 2015-December 2017) that included 301 adults with moderate to severe ARDS according to the Berlin definition. The radiological and partial pressure of oxygen, arterial (Pao2)/fraction of inspired oxygen (Fio2) criteria for ARDS had to be met within a 24-hour period, and the administration of the first dose of the study drug had to occur within 48 hours of the diagnosis of ARDS. The last patient visit was on March 6, 2018. Interventions: Patients were randomized to receive an intravenous injection of 10 μg of IFN-β-1a (144 patients) or placebo (152 patients) once daily for 6 days. Main Outcomes and Measures: The primary outcome was a score combining death and number of ventilator-free days at day 28 (score ranged from -1 for death to 27 if the patient was off ventilator on the first day). There were 16 secondary outcomes, including 28-day mortality, which were tested hierarchically to control type I error. Results: Among 301 patients who were randomized (mean age, 58 years; 103 women [34.2%]), 296 (98.3%) completed the trial and were included in the primary analysis. At 28 days, the median composite score of death and number of ventilator-free days at day 28 was 10 days (interquartile range, -1 to 20) in the IFN-β-1a group and 8.5 days (interquartile range, 0 to 20) in the placebo group (P = .82). There was no significant difference in 28-day mortality between the IFN-β-1a vs placebo groups (26.4% vs 23.0%; difference, 3.4% [95% CI, -8.1% to 14.8%]; P = .53). Seventy-four patients (25.0%) experienced adverse events considered to be related to treatment during the study (41 patients [28.5%] in the IFN-β-1a group and 33 [21.7%] in the placebo group). Conclusions and Relevance: Among adults with moderate or severe ARDS, intravenous IFN-β-1a administered for 6 days, compared with placebo, resulted in no significant difference in a composite score that included death and number of ventilator-free days over 28 days. These results do not support the use of IFN-β-1a in the management of ARDS. Trial Registration: ClinicalTrials.gov Identifier: NCT02622724.
Authors: Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Ronan Lordan; Yanjun Qi; Yuchen Sun; Christian Brueffer; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ashwin N Skelly; Bharath Ramsundar; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene Journal: mSystems Date: 2021-11-02 Impact factor: 6.496
Authors: George W Williams; Nathaniel K Berg; Alexander Reskallah; Xiaoyi Yuan; Holger K Eltzschig Journal: Anesthesiology Date: 2021-02-01 Impact factor: 7.892
Authors: Juan Pablo Sosa; Maria Mercedes Ferreira Caceres; Jennifer Ross Comptis; Jorge Quiros; Fortunato S Príncipe-Meneses; Adrian Riva-Moscoso; Marie Pierre Belizaire; Freda Q Malanyaon; Kuchalambal Agadi; Syeda Sheharbano Jaffery; Juhi Sahajwani; Asma Arshia; Andrelle Senatus; Graciela Verdecia; Lordstrong Akano; Aminah Abdul Razzack; Sanna Salam; Vinay Kumar Gadamidi; Sheeba Marian Journal: Infect Chemother Date: 2021-06
Authors: Shahd Horie; Bairbre McNicholas; Emanuele Rezoagli; Tài Pham; Ger Curley; Danny McAuley; Cecilia O'Kane; Alistair Nichol; Claudia Dos Santos; Patricia R M Rocco; Giacomo Bellani; John G Laffey Journal: Intensive Care Med Date: 2020-07-11 Impact factor: 41.787